160 related articles for article (PubMed ID: 30562853)
21. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
22. [Progression of immunotherapy in gastric cancer].
Wei X; Xu R
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
[TBL] [Abstract][Full Text] [Related]
23. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
24. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
25. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
26. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab: targeting PD-1 to bolster antitumor immunity.
Brahmer JR; Hammers H; Lipson EJ
Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
[TBL] [Abstract][Full Text] [Related]
28. Programmed death 1 immune checkpoint inhibitors.
Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
[TBL] [Abstract][Full Text] [Related]
29. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab for the treatment of hepatocellular carcinoma.
Finkelmeier F; Waidmann O; Trojan J
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
[TBL] [Abstract][Full Text] [Related]
31. Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells.
Akiyama Y; Nonomura C; Kondou R; Miyata H; Ashizawa T; Maeda C; Mitsuya K; Hayashi N; Nakasu Y; Yamaguchi K
Int J Oncol; 2016 Sep; 49(3):1099-107. PubMed ID: 27573705
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
33. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
34. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
35. Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy.
Giuroiu I; Weber J
Cancer J; 2017; 23(1):23-31. PubMed ID: 28114251
[TBL] [Abstract][Full Text] [Related]
36. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.
Dolan DE; Gupta S
Cancer Control; 2014 Jul; 21(3):231-7. PubMed ID: 24955707
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Sweis RF; Luke JJ
Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]